Organogenesis Holdings Valuation
| ORGO Stock | USD 4.04 0.01 0.25% |
At this time, the company appears to be overvalued. Organogenesis Holdings holds a recent Real Value of $3.63 per share. The prevailing price of the company is $4.04. Our model determines the value of Organogenesis Holdings from analyzing the company fundamentals such as Shares Outstanding of 132.58 M, operating margin of 0.05 %, and Return On Equity of -0.0266 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Organogenesis Holdings' valuation include:
Price Book 1.9276 | Enterprise Value 550.3 M | Enterprise Value Ebitda 45.39 | Price Sales 1.18 | Forward PE 12.3153 |
Overvalued
Today
Please note that Organogenesis Holdings' price fluctuation is risky at this time. Calculation of the real value of Organogenesis Holdings is based on 3 months time horizon. Increasing Organogenesis Holdings' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Organogenesis Holdings is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Organogenesis Stock. However, Organogenesis Holdings' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.04 | Real 3.63 | Target 3.5 | Hype 4.09 | Naive 4.13 |
The intrinsic value of Organogenesis Holdings' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Organogenesis Holdings' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Organogenesis Holdings helps investors to forecast how Organogenesis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Organogenesis Holdings more accurately as focusing exclusively on Organogenesis Holdings' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Organogenesis Holdings' intrinsic value based on its ongoing forecasts of Organogenesis Holdings' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Organogenesis Holdings' closest peers.
Organogenesis Holdings Cash |
|
Organogenesis Valuation Trend
Knowing Organogenesis Holdings' actual value is paramount for traders when making sound investment determinations. Using both Organogenesis Holdings' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Organogenesis Revenue by Product
Organogenesis Holdings Total Value Analysis
Organogenesis Holdings is now forecasted to have valuation of 550.26 M with market capitalization of 536.94 M, debt of 119.35 M, and cash on hands of 113.24 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Organogenesis Holdings fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
550.26 M | 536.94 M | 119.35 M | 113.24 M |
Organogenesis Holdings Investor Information
About 43.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.93. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Organogenesis Holdings recorded a loss per share of 0.05. The entity had not issued any dividends in recent years. Based on the key indicators related to Organogenesis Holdings' liquidity, profitability, solvency, and operating efficiency, Organogenesis Holdings is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in December.Organogenesis Holdings Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Organogenesis Holdings has an asset utilization ratio of 94.16 percent. This suggests that the Company is making $0.94 for each dollar of assets. An increasing asset utilization means that Organogenesis Holdings is more efficient with each dollar of assets it utilizes for everyday operations.Organogenesis Holdings Ownership Allocation
Organogenesis Holdings owns a total of 132.58 Million outstanding shares. Organogenesis Holdings has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Organogenesis Holdings Profitability Analysis
The company reported the previous year's revenue of 433.14 M. Net Income was 4.95 M with profit before overhead, payroll, taxes, and interest of 345.87 M.About Organogenesis Holdings Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Organogenesis Holdings. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Organogenesis Holdings based exclusively on its fundamental and basic technical indicators. By analyzing Organogenesis Holdings's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Organogenesis Holdings's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Organogenesis Holdings. We calculate exposure to Organogenesis Holdings's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Organogenesis Holdings's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 309.8 M | 178 M | |
| Pretax Profit Margin | 0.02 | 0.03 | |
| Operating Profit Margin | 0.03 | 0.03 | |
| Net Profit Margin | 0.01 | 0.01 | |
| Gross Profit Margin | 0.72 | 0.58 |
Organogenesis Holdings Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 132.7 M | |
| Quarterly Earnings Growth Y O Y | 3.5 | |
| Forward Price Earnings | 12.3153 |
Organogenesis Holdings Current Valuation Indicators
Organogenesis Holdings' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Organogenesis Holdings' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Organogenesis Holdings, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Organogenesis Holdings' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Organogenesis Holdings' worth.When determining whether Organogenesis Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Organogenesis Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organogenesis Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organogenesis Holdings Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 3.5 | Earnings Share (0.05) | Revenue Per Share 3.446 | Quarterly Revenue Growth 0.061 | Return On Assets 0.0164 |
The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.